Additionally, modulation of the hepcidin-ferroportin axis and nanotechnology-based iron-targeting approaches offer innovative avenues to selectively disrupt iron availability in breast cancer cells while minimizing systemic toxicity. This evidence concerns the gene SLC40A1 and breast cancer.